Silence Therapeutics (SLN) Projected to Post Earnings on Thursday

Silence Therapeutics (NASDAQ:SLN) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Silence Therapeutics to post earnings of ($0.16) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Silence Therapeutics Stock Performance

Shares of SLN stock opened at $4.69 on Wednesday. Silence Therapeutics has a 52-week low of $4.06 and a 52-week high of $27.72. The firm has a market capitalization of $140.37 million, a P/E ratio of -2.99 and a beta of 1.05. The stock has a 50 day moving average price of $5.75 and a 200 day moving average price of $11.99.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. BMO Capital Markets reissued an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Wednesday, January 29th. The Goldman Sachs Group initiated coverage on Silence Therapeutics in a report on Tuesday, February 11th. They set a “sell” rating and a $6.00 price objective on the stock. Chardan Capital restated a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday, December 10th. Finally, William Blair restated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $45.00.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.